With so many biosimilars in the U.S. pipeline, the federal government has had its hands full in recent months managing legislation and expectations from patient groups, health organizations, pharmaceutical companies and advocates. While debates rage on and in-fighting has severed several previously harmonious relationships, the fall is expected to bring some big changes to the
Read More
About The Author
